Iasibon (Ibandronic Acid)

Ibandronic acid binds to bone mineral at sites of active remodeling. When osteoclasts attach to this drug‑coated surface, it blocks the mevalonate pathway, preventing essential protein prenylation. This impairs osteoclast function and triggers their apoptosis, leading to decreased bone breakdown.

The specific dose and infusion schedule of Iasibon are determined by the prescribing clinician based on the patient’s indication, renal function, and overall health. Healthcare professionals follow approved labeling and clinical guidelines to set the appropriate regimen.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided in pregnant or nursing women because potential risks to the fetus or infant cannot be excluded. Clinicians should discuss alternative options when treatment is needed in these populations.

To place an order, submit an enquiry on the Iasibon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iasibon (ibandronic acid) is a potent nitrogen‑containing bisphosphonate administered intravenously, offering a convenient dosing interval compared with some oral agents. Compared with alternatives like zoledronic acid, ibandronate has a similar mechanism but may be chosen based on physician preference, patient tolerance, and specific dosing schedules.

Iasibon should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Iasibon is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically delivered over a short period (often 15‑30 minutes) following appropriate pre‑infusion assessments, such as checking calcium levels and renal function.

Serious risks include acute renal impairment, severe hypocalcemia, osteonecrosis of the jaw, and rare anaphylactic reactions. Patients should be monitored for signs of kidney dysfunction, calcium disturbances, and any oral symptoms, and should receive dental evaluation before starting therapy.

Iasibon is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid, or active dental infections. Caution is also advised for individuals with uncontrolled hypocalcemia, pregnant or nursing women, and those with a history of atrial fibrillation.